New drug combo targets Hard-to-Treat thyroid cancer
NCT ID NCT01947023
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This early-phase study tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that could not be removed by surgery and had stopped responding to standard treatments. The goal was to find the safest dose of lapatinib when given with dabrafenib and to see if the combination could slow or stop tumor growth by blocking specific proteins that help cancer cells grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYROID GLAND CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.